Clin Nutr Res.  2015 Jul;4(3):137-152. 10.7762/cnr.2015.4.3.137.

Nutritional Management of Kidney Stones (Nephrolithiasis)

Affiliations
  • 1Department of Nephrology, Harvard Vanguard Medical Associate, Boston, MA 02115, USA. hhan1@comcast.net, haewookhan@gmail.com
  • 2Harvard Vanguard Medical Associate, Clinical Instructor at Harvard Medical School, Boston, MA 02115, USA.
  • 3Harvard Vanguard Medical Associates; Brigham and Women's Hospital, Boston, MA 02115, USA.
  • 4Tufts University Friedman School of Nutrition and School of Medicine, Boston, MA 02111, USA.

Abstract

The incidence of kidney stones is common in the United States and treatments for them are very costly. This review article provides information about epidemiology, mechanism, diagnosis, and pathophysiology of kidney stone formation, and methods for the evaluation of stone risks for new and follow-up patients. Adequate evaluation and management can prevent recurrence of stones. Kidney stone prevention should be individualized in both its medical and dietary management, keeping in mind the specific risks involved for each type of stones. Recognition of these risk factors and development of long-term management strategies for dealing with them are the most effective ways to prevent recurrence of kidney stones.

Keyword

Nephrolithiasis; Calcium oxalate; Uric acid stone; Hypercalciuria; Hyperoxaluria; Risk factors for kidney stones; Prevention of kidney stone

MeSH Terms

Calcium Oxalate
Diagnosis
Epidemiology
Humans
Hypercalciuria
Hyperoxaluria
Incidence
Kidney Calculi*
Kidney*
Nephrolithiasis
Recurrence
Risk Factors
United States
Calcium Oxalate

Figure

  • Figure 1 Type of stones. Light microscopy of urine crystals. (A) Hexagonal cystine crystal (200X); (B) coffin-lid shaped struvite crystals (200X); (C) pyramid-shaped calcium oxalate dehydrate crystals (200X); (D) dumbbell-shaped calcium oxalate monohydrate crystal (400X); (E) rectangular uric acid crystals (400X); and (F) rhomboidal uric acid crystals (400X). Reprinted with permission by Elsevier and reference [12].

  • Figure 2 Model of idiopathic hypercalciuria.

  • Figure 3 Extracorporeal shock wave lithotripsy (ESWL).


Cited by  1 articles

A prediction model of Nephrolithiasis Risk: A population-based cohort study in Korea
David Mukasa, Joohon Sung
Investig Clin Urol. 2020;61(2):188-199.    doi: 10.4111/icu.2020.61.2.188.


Reference

1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003; 63:1817–1823.
Article
2. Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012; 62:160–165.
Article
3. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol. 1998; 9:1645–1652.
Article
4. Stapleton AE, Dziura J, Hooton TM, Cox ME, Yarova-Yarovaya Y, Chen S, Gupta K. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc. 2012; 87:143–150.
Article
5. Goldfarb DS. In the clinic. Nephrolithiasis. Ann Intern Med. 2009; 151:ITC2.
6. Pearle MS. Prevention of nephrolithiasis. Curr Opin Nephrol Hypertens. 2001; 10:203–209.
Article
7. Pearle MS, Calhoun EA, Curhan GC. Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol. 2005; 173:848–857.
Article
8. Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S, Goldfarb D, Grasso M, Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998; 159:1821–1825.
Article
9. Asplin JR. Nephrolithiasis: introduction. Semin Nephrol. 2008; 28:97–98.
Article
10. Coe FL, Wise H, Parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001; 166:1247–1251.
Article
11. Borghi L, Guerra A, Meschi T, Briganti A, Schianchi T, Allegri F, Novarini A. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int. 1999; 55:1041–1050.
Article
12. Asplin JR. Evaluation of the kidney stone patient. Semin Nephrol. 2008; 28:99–110.
Article
13. Finkielstein VA, Goldfarb DS. Strategies for preventing calcium oxalate stones. CMAJ. 2006; 174:1407–1409.
Article
14. Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab. 1990; 71:861–867.
Article
15. Lemann J Jr, Worcester EM, Gray RW. Hypercalciuria and stones. Am J Kidney Dis. 1991; 17:386–391.
Article
16. Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008; 35:369–391. vii
Article
17. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008; 28:120–132.
Article
18. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002; 31:927–949.
Article
19. Borghi L, Meschi T, Maggiore U, Prati B. Dietary therapy in idiopathic nephrolithiasis. Nutr Rev. 2006; 64:301–312.
Article
20. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002; 346:77–84.
Article
21. Curhan GC. Dietary calcium, dietary protein, and kidney stone formation. Miner Electrolyte Metab. 1997; 23:261–264.
22. Curhan GC, Curhan SG. Dietary factors and kidney stone formation. Compr Ther. 1994; 20:485–489.
23. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol. 1996; 155:1847–1851.
Article
24. Taylor EN, Curhan GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol. 2007; 18:2198–2204.
Article
25. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993; 328:833–838.
Article
26. Dawson CH, Tomson CR. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med. 2012; 12:467–471.
Article
27. Eisner BH, Goldfarb DS. A nomogram for the prediction of kidney stone recurrence. J Am Soc Nephrol. 2014; 25:2685–2687.
Article
28. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007; 177:565–569.
Article
29. Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol. 2008; 28:163–173.
Article
30. Cameron MA, Sakhaee K. Uric acid nephrolithiasis. Urol Clin North Am. 2007; 34:335–346.
Article
31. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992; 327:1141–1152.
Article
32. Moran ME. Uric acid stone disease. Front Biosci. 2003; 8:s1339–s1355.
Article
33. Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis. 2010; 3:1–10.
34. Kenny JE, Goldfarb DS. Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep. 2010; 12:125–129.
Article
35. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008; 73:489–496.
Article
36. Fattah H, Hambaroush Y, Goldfarb DS. Cystine nephrolithiasis. Transl Androl Urol. 2014; 3:228–233.
37. Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol. 2008; 28:181–191.
Article
38. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones--pathogenesis, microbiology, and management strategies. Nat Rev Urol. 2014; 11:333–341.
Article
39. Romero-Vargas L, Barba Abad J, Rosell Costa D, Pascual Piedrola JI. Staghorn stones in renal graft. Presentation on two cases report and review the bibliography. Arch Esp Urol. 2014; 67:650–653.
40. Trinchieri A. Urinary calculi and infection. Urologia. 2014; 81:93–98.
Article
41. Eisner BH, McQuaid JW, Hyams E, Matlaga BR. Nephrolithiasis: what surgeons need to know. AJR Am J Roentgenol. 2011; 196:1274–1278.
Article
42. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol. 1997; 8:1568–1573.
Article
43. Parks JH, Coe FL, Evan AP, Worcester EM. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU Int. 2009; 103:670–678.
Article
44. Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol. 2002; 167:1607–1612.
Article
45. Fakheri RJ, Goldfarb DS. Association of nephrolithiasis prevalence rates with ambient temperature in the United States: a re-analysis. Kidney Int. 2009; 76:798.
Article
46. Fakheri RJ, Goldfarb DS. Ambient temperature as a contributor to kidney stone formation: implications of global warming. Kidney Int. 2011; 79:1178–1185.
Article
47. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int. 2008; 73:207–212.
Article
48. Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol. 2013; 190:1255–1259.
Article
49. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol. 2004; 15:3225–3232.
Article
50. Ticinesi A, Nouvenne A, Maalouf NM, Borghi L, Meschi T. Salt and nephrolithiasis. Nephrol Dial Transplant. Forthcoming 2014.
Article
51. Atan L, Andreoni C, Ortiz V, Silva EK, Pitta R, Atan F, Srougi M. High kidney stone risk in men working in steel industry at hot temperatures. Urology. 2005; 65:858–861.
Article
52. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996; 155:839–843.
Article
53. Goldfarb DS, Coe FL. Beverages, diet, and prevention of kidney stones. Am J Kidney Dis. 1999; 33:398–400.
Article
54. Nouvenne A, Meschi T, Guerra A, Allegri F, Prati B, Borghi L. Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab. 2008; 5:135–141.
55. Taylor EN, Curhan GC. Diet and fluid prescription in stone disease. Kidney Int. 2006; 70:835–839.
Article
56. Ticinesi A, Nouvenne A, Borghi L, Meschi T. Water and other fluids in nephrolithiasis: state of the art and future challenges. Crit Rev Food Sci Nutr. Forthcoming 2015.
Article
57. Worcester EM, Coe FL, Evan AP, Bergsland KJ, Parks JH, Willis LR, Clark DL, Gillen DL. Evidence for increased postprandial distal nephron calcium delivery in hypercalciuric stone-forming patients. Am J Physiol Renal Physiol. 2008; 295:F1286–F1294.
Article
58. Taylor EN, Curhan GC. Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol. 2008; 3:1453–1460.
Article
59. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68:1230–1235.
Article
60. Tasca A. Metabolic syndrome and bariatric surgery in stone disease etiology. Curr Opin Urol. 2011; 21:129–133.
Article
61. Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG. Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol. 2011; 186:135–139.
Article
62. Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005; 68:1244–1249.
63. Ashby RA, Sleet RJ. The role of citrate complexes in preventing urolithiasis. Clin Chim Acta. 1992; 210:157–165.
Article
64. Kessler T, Hesse A. Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr. 2000; 84:865–871.
Article
65. Kessler T, Jansen B, Hesse A. Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. Eur J Clin Nutr. 2002; 56:1020–1023.
Article
66. Mahan LK, Escott-Stump S. Krause's food & nutrition therapy. 12th ed. St. Louis (MO): Elsevier Saunders;2008.
67. Nouvenne A, Meschi T, Prati B, Guerra A, Allegri F, Vezzoli G, Soldati L, Gambaro G, Maggiore U, Borghi L. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am J Clin Nutr. 2010; 91:565–570.
Article
68. Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009; 20:2253–2259.
Article
69. Taylor EN, Stampfer MJ, Mount DB, Curhan GC. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol. 2010; 5:2315–2322.
Article
70. Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol. 2006; 17:1422–1428.
Article
71. Massey LK, Kynast-Gales SA. Diets with either beef or plant proteins reduce risk of calcium oxalate precipitation in patients with a history of calcium kidney stones. J Am Diet Assoc. 2001; 101:326–331.
Article
72. Sorensen MD, Kahn AJ, Reiner AP, Tseng TY, Shikany JM, Wallace RB, Chi T, Wactawski-Wende J, Jackson RD, O'Sullivan MJ, Sadetsky N, Stoller ML. WHI Working Group. Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS. J Urol. 2012; 187:1645–1649.
Article
73. Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis. 2014; 63:456–463.
Article
74. Grases F, March JG, Prieto RM, Simonet BM, Costa-Bauzá A, García-Raja A, Conte A. Urinary phytate in calcium oxalate stone formers and healthy people-dietary effects on phytate excretion. Scand J Urol Nephrol. 2000; 34:162–164.
Article
75. Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology. 2007; 69:1013–1016.
Article
76. Grases F, Costa-Bauzá A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res. 1999; 19:3717–3722.
77. Grases F, Costa-Bauza A, Prieto RM. Renal lithiasis and nutrition. Nutr J. 2006; 5:23.
Article
78. Grases F, Isern B, Sanchis P, Perello J, Torres JJ, Costa-Bauza A. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci. 2007; 12:2580–2587.
Article
79. Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med. 2004; 350:684–693.
80. Pennington JA, Spungen JS. Bowes & Church's food values of portions commonly used. 19th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2010.
81. Chai W, Liebman M. Oxalate content of legumes, nuts, and grain-based flours. J Food Compost Anal. 2005; 18:723–729.
Article
82. Judprasong K, Charoenkiatkul S, Sungpuag P, Vasanachitt K, Nakjamanong Y. Total and soluble oxalate contents in Thai vegetables, cereal grains and legume seeds and their changes after cooking. J Food Compost Anal. 2006; 19:340–347.
Article
83. United States Department of Agriculture Agricultural Research Service. Oxalic acid content of selected vegetables. 2005. cited 2015 July 6. Available from http://www.ars.usda.gov/Services/docs.htm?docid=9444.
84. Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis. 2013; 20:165–174.
Article
Full Text Links
  • CNR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr